Yujiro S. Hata is the Founder, President, and Chief Executive Officer of IDEAYA Biosciences, a precision oncology company he established in 2015. Under his leadership, IDEAYA has grown from a startup into a publicly traded biotechnology company, completing its initial public offering on the NASDAQ in 2019. The company has secured significant capital through public markets and strategic collaborations, enabling the advancement of a diversified pipeline focused on genetically defined cancer populations. IDEAYA integrates small-molecule drug discovery, translational biology, and biomarker-driven patient selection to develop targeted therapies aimed at improving outcomes in oncology.
During Hata’s tenure, IDEAYA has built a strong presence in the field of precision medicine and synthetic lethality research, advancing multiple clinical and preclinical programs and establishing partnerships with leading global pharmaceutical companies. The organization has achieved key clinical milestones across its oncology portfolio and earned recognition within the biotechnology industry for its scientific approach and execution. Through sustained investment in research, disciplined capital allocation, and strategic collaboration, Hata has positioned IDEAYA Biosciences as a notable innovator in targeted cancer therapeutics.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential CEOs in Oncology in 2025 and stay tuned for other special category nominations
